This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Fate Therapeutics launched through $14.6mm Series A
Fate Therapeutics (adult stem cell biology) was recently launched through a two-tranche $14.6mm Series A round backed by Arch Venture Partners, Polaris Venture Partners, OVP Venture Partners, and Venrock. The start-up has a small-molecule platform that modulates adult stem cells to mimic the beneficial characteristics of embryonic stem cells.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?